ممکن است صدای این قسمت خراب باشد.
How to fix it?
درباره این اپیزود
Listen to Tina Wang, Statistician, and Dr. Paul Schuette, Deputy Division Director, in the Office of Biostatistics Division of Analytics and Informatics within FDA’s Center for Drug Evaluation and Research discuss FDA’s experiences with a centralized statistical monitoring tool.
انگلیسی
ایالات متحده آمریکا
جستجوی اپیزودهای گذشته
اپیزودهای قبلی FDA CDER Small Business and Industry Assistance (SBIA) Chronicles را جستجو کن.
قسمت های دیگر در این پادکست
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
سلب مسئولیت: پادکست و آثار هنری تعبیه شده در این صفحه متعلق به U.S. Food and Drug Administration, Center for Drug Evaluation and Research است که متعلق به صاحب آن است و به Listen Notes، Inc وابسته یا تایید نشده است.
ویرایش
از کمک شما برای بروز نگهداشتن پایگاهدادههای پادکست سپاسگزاریم
